Cencora (COR) Fundamentals 2026 — P/E 23.0x, Revenue Analysis | SniperIQ
Cencora (COR) is a US-listed Healthcare company in Medical - Distribution with a market capitalization of $58.8B, trading at
Cencora (COR) has a market capitalization of approximately $58.8B, trading at
Cencora's trailing twelve-month P/E ratio is 23.0x, with a price-to-book (P/B) of 17.3x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
Cencora runs a net profit margin of 0.8%, a gross margin of 3.5%, and an operating margin of 1.3%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
Cencora reported revenue of
Cencora offers a trailing dividend yield of about 0.8%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Cencora carries a debt-to-equity ratio of 3.65x and a current ratio of 0.95x, with a market beta of 0.58. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Cencora (COR) the key facts are: market cap $58.8B, P/E 23.0x, revenue
Get Cencora's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.